Dimensional Fund Advisors LP Has $171,000 Stock Holdings in G1 Therapeutics, Inc. (NASDAQ:GTHX)

Dimensional Fund Advisors LP lessened its stake in G1 Therapeutics, Inc. (NASDAQ:GTHX) by 3.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 74,826 shares of the company’s stock after selling 2,705 shares during the quarter. Dimensional Fund Advisors LP owned 0.14% of G1 Therapeutics worth $171,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in GTHX. Vanguard Group Inc. grew its position in G1 Therapeutics by 5.0% in the first quarter. Vanguard Group Inc. now owns 2,081,573 shares of the company’s stock worth $8,992,000 after acquiring an additional 99,900 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of G1 Therapeutics by 643.2% during the 1st quarter. Acadian Asset Management LLC now owns 433,709 shares of the company’s stock worth $1,873,000 after buying an additional 375,354 shares during the period. Panagora Asset Management Inc. bought a new stake in shares of G1 Therapeutics during the 2nd quarter worth $404,000. SG Americas Securities LLC bought a new stake in shares of G1 Therapeutics during the 1st quarter worth $58,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of G1 Therapeutics during the 2nd quarter worth $48,000. Institutional investors and hedge funds own 24.21% of the company’s stock.

Analyst Ratings Changes

GTHX has been the subject of a number of research reports. HC Wainwright downgraded shares of G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. Wedbush downgraded shares of G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of G1 Therapeutics in a research note on Wednesday, August 7th.

G1 Therapeutics Stock Performance

Shares of G1 Therapeutics stock opened at $7.15 on Tuesday. The stock has a market capitalization of $373.81 million, a P/E ratio of -11.53 and a beta of 1.66. The company has a quick ratio of 2.12, a current ratio of 2.48 and a debt-to-equity ratio of 1.34. The company has a 50-day simple moving average of $7.07 and a 200 day simple moving average of $4.88. G1 Therapeutics, Inc. has a 12-month low of $1.08 and a 12-month high of $7.19.

G1 Therapeutics (NASDAQ:GTHX) last announced its earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The business had revenue of $16.55 million during the quarter, compared to analysts’ expectations of $15.88 million. G1 Therapeutics had a negative net margin of 76.93% and a negative return on equity of 136.98%. Research analysts expect that G1 Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.